CAS NO: | 225937-10-0 |
包装 | 价格(元) |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | (+)-Catechin hydrate inhibits cyclooxygenase-1 (COX-1) with anIC50of 1.4 μM. | ||||||||||||
IC50& Target[1] |
| ||||||||||||
体外研究 (In Vitro) | (+)-Catechin exhibits >95% inhibitory activity at 70 μg/mL against cyclooxygenase-1 (COX-1) with an IC50of 1.4 μM[1]. A dose-dependent reduction in color is observed after 24 hours of treatment with (+)-Catechin, and 54.76% of the cells are dead at the highest concentration of (+)-Catechin tested (160 μg/mL) whereas the IC50of (+)-Catechin is achieved at 127.62 μg/mL (+)-Catechin. A dose- and time-dependent increase in the induction of apoptosis is observed when MCF-7 cells are treated with (+)-Catechin. When compare to the control cells at 24 hours, 40.7 and 41.16% of the cells treated with 150 μg/mL and 300 μg/mL (+)-Catechin, respectively, undergo apoptosis. The expression levels ofCaspase-3,-8, and-9andp53in MCF-7 cells treated with 150 μg/mL (+)-Catechin for 24 h increase by 5.81, 1.42, 3.29, and 2.68 fold, respectively, as compare to the levels in untreated control cells[2]. | ||||||||||||
体内研究 (In Vivo) | Animals treated with (+)-Catechin at the lowest tested dose, i.e., 50 mg/kg, p.o. have spent comparatively more time in exploring the novel object in the choice trial, however, the difference is not statistically significant. (+)-Catechin prevents the time-induced episodic memory deficits in a dose-dependent manner, the most effective being 200 mg/kg, p.o.. Treatment with (+)-Catechin prevents the rise in MPO level compare to DOX alone treatment group (21.98±9.44 and 36.76±4.39% in the hippocampus and the frontal cortex respectively)[3]. | ||||||||||||
Clinical Trial | |||||||||||||
性状 | Solid | ||||||||||||
Formula | C15H14O6.xH2O | ||||||||||||
CAS 号 | 225937-10-0 | ||||||||||||
中文名称 | (+)-水合儿茶素 | ||||||||||||
结构分类 |
| ||||||||||||
来源 |
| ||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||
储存方式 |
| ||||||||||||
溶解性数据 | In Vitro: DMSO : 50 mg/mL(Need ultrasonic) In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|